Primary care physician practices in the diagnosis, treatment and management of men with chronic prostatitis/chronic pelvic pain syndrome.

abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...

journal_title：Prostate cancer and prostatic diseases

authors： Sadetsky N,Elkin EP,Latini DM,DuChane J,Carroll PR,CaPSURE Investigators.

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

journal_title：Prostate cancer and prostatic diseases

authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

更新日期：2016-03-01 00:00:00

abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

journal_title：Prostate cancer and prostatic diseases

authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...

journal_title：Prostate cancer and prostatic diseases

authors： Lu JP,Hou ZF,Duivenvoorden WC,Whelan K,Honig A,Pinthus JH

更新日期：2012-03-01 00:00:00

abstract：:The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prost...

journal_title：Prostate cancer and prostatic diseases

authors： Valicenti RK

更新日期：2002-01-01 00:00:00

abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

journal_title：Prostate cancer and prostatic diseases

authors： Potters L,Fearn P,Kattan M

更新日期：2002-01-01 00:00:00

abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...

journal_title：Prostate cancer and prostatic diseases

authors： Hammarsten J,Högstedt B,Holthuis N,Mellström D

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

journal_title：Prostate cancer and prostatic diseases

authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

更新日期：2019-09-01 00:00:00

abstract：:Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...

journal_title：Prostate cancer and prostatic diseases

authors： Oades GM,Coxon J,Colston KW

更新日期：2002-01-01 00:00:00

abstract：:The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom...

journal_title：Prostate cancer and prostatic diseases

authors： Dunsmuir WD,McFarlane JP,Tan A,Dowling C,Downie J,Kourambas J,Donnellan S,Redgrave N,Fletcher R,Frydenberg M,Love C

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

journal_title：Prostate cancer and prostatic diseases

authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

更新日期：2019-09-01 00:00:00

abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

journal_title：Prostate cancer and prostatic diseases

authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

更新日期：2011-12-01 00:00:00

abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

更新日期：2009-01-01 00:00:00

abstract：:Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treat...

journal_title：Prostate cancer and prostatic diseases

authors： Tomic R,Ljungberg B

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

journal_title：Prostate cancer and prostatic diseases

authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

更新日期：2019-12-01 00:00:00

abstract：INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...

journal_title：Prostate cancer and prostatic diseases

authors： Shah TT,Reddy D,Peters M,Ball D,Kim NH,Gomez EG,Miah S,Evans DE,Guillaumier S,van Rossum PSN,Van Son MJ,Hosking-Jervis F,Dudderidge T,Hindley R,Emara A,McCracken S,Greene D,Nigam R,McCartan N,Valerio M,Minhas S,

更新日期：2021-01-28 00:00:00

abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

journal_title：Prostate cancer and prostatic diseases

authors： Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

journal_title：Prostate cancer and prostatic diseases

authors： Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...

journal_title：Prostate cancer and prostatic diseases

authors： Jang WS,Yoon CY,Kim MS,Kang DH,Kang YJ,Jeong WS,Abalajon MJ,Ham WS,Choi YD

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of...

journal_title：Prostate cancer and prostatic diseases

authors： Hagiwara M,Delea TE,Saville MW,Chung K

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

journal_title：Prostate cancer and prostatic diseases

authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

更新日期：2014-09-01 00:00:00

abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Rossi PJ,Jani AB,Master V

更新日期：2007-01-01 00:00:00

abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

journal_title：Prostate cancer and prostatic diseases

authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

更新日期：2000-12-01 00:00:00

abstract：:We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...

journal_title：Prostate cancer and prostatic diseases

authors： Veltri RW,Park J,Miller MC,Marks L,Kojima M,van Rootselaar C,Khan MA,Partin AW

更新日期：2004-01-01 00:00:00

abstract：:Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

journal_title：Prostate cancer and prostatic diseases

authors： Goetzl MA,Van Veldhuizen PJ,Thrasher JB

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

journal_title：Prostate cancer and prostatic diseases

authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

更新日期：2020-07-31 00:00:00

abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

journal_title：Prostate cancer and prostatic diseases

authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

更新日期：2020-09-03 00:00:00

abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

journal_title：Prostate cancer and prostatic diseases

authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

更新日期：2013-12-01 00:00:00

abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...

journal_title：Prostate cancer and prostatic diseases

authors： Diss JK,Stewart D,Pani F,Foster CS,Walker MM,Patel A,Djamgoz MB

更新日期：2005-01-01 00:00:00